U.S. patent application number 12/208543 was filed with the patent office on 2009-01-08 for novel compounds.
This patent application is currently assigned to Glaxo Group Limited. Invention is credited to Gregor James MacDonald, Mervyn Thompson.
Application Number | 20090012099 12/208543 |
Document ID | / |
Family ID | 9954569 |
Filed Date | 2009-01-08 |
United States Patent
Application |
20090012099 |
Kind Code |
A1 |
MacDonald; Gregor James ; et
al. |
January 8, 2009 |
Novel Compounds
Abstract
Disclosed is a method for use of phenyl sulfone compounds of
formula (I) in the treatment of Alzheimer's disease and age related
cognitive decline. ##STR00001##
Inventors: |
MacDonald; Gregor James;
(Harlow, GB) ; Thompson; Mervyn; (Harlow,
GB) |
Correspondence
Address: |
GLAXOSMITHKLINE;Corporate Intellectual Property - UW2220
P.O.Box 1539
King Prussia
PA
19406-0939
US
|
Assignee: |
Glaxo Group Limited
|
Family ID: |
9954569 |
Appl. No.: |
12/208543 |
Filed: |
September 11, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12119759 |
May 13, 2008 |
7439245 |
|
|
12208543 |
|
|
|
|
11828389 |
Jul 26, 2007 |
|
|
|
12119759 |
|
|
|
|
10547987 |
Sep 8, 2005 |
7262188 |
|
|
PCT/EP2004/002554 |
Mar 9, 2004 |
|
|
|
11828389 |
|
|
|
|
Current U.S.
Class: |
514/255.03 |
Current CPC
Class: |
C07D 295/096 20130101;
A61P 25/00 20180101; A61P 3/04 20180101; A61P 25/24 20180101; A61P
25/22 20180101; A61P 25/18 20180101; A61P 25/28 20180101 |
Class at
Publication: |
514/255.03 |
International
Class: |
A61K 31/495 20060101
A61K031/495; A61P 25/28 20060101 A61P025/28 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 11, 2003 |
GB |
0305575.3 |
Claims
1. A method of treating Alzheimer's disease which comprises
administering a therapeutically effective amount of a compound of
the following formula, or a pharmaceutically acceptable salt
thereof, to a patient in need thereof: ##STR00006## wherein:
R.sup.1 and R.sup.2 independently represent hydrogen or C.sub.1-6
alkyl; R.sup.3 independently represents hydrogen or halogen; m and
n both represent 1; and p represents 1 or 2.
2. The method of claim 1 wherein said compound is:
1-(3-Phenylsulfonyl-phenyl)piperazine;
1-(3-Phenylsulfonyl-2-chlorophenyl)piperazine; or
1-(5-Phenylsulfonyl-2-chlorophenyl)piperazine; or a
pharmaceutically acceptable salt thereof.
3. A method of treating Alzheimer's disease according to claim 1
which comprises administering a pharmaceutical composition which
comprises the compound or salt as defined in claim 1 and a
pharmaceutically acceptable carrier or excipient.
4. A method of treating age related cognitive decline which
comprises administering a therapeutically effective amount of a
compound of the following formula, or a pharmaceutically acceptable
salt thereof, to a patient in need thereof: ##STR00007## wherein:
R.sup.1 and R.sup.2 independently represent hydrogen or C.sub.1-6
alkyl; R.sup.3 independently represents hydrogen or halogen; m and
n both represent 1; and p represents 1 or 2.
5. The method of claim 4 wherein said compound is:
1-(3-Phenylsulfonyl-phenyl)piperazine;
1-(3-Phenylsulfonyl-2-chlorophenyl)piperazine; or
1-(5-Phenylsulfonyl-2-chlorophenyl)piperazine; or a
pharmaceutically acceptable salt thereof.
6. A method of treating age related cognitive decline according to
claim 4 which comprises administering a pharmaceutical composition
which comprises the compound or salt as defined in claim 4 and a
pharmaceutically acceptable carrier or excipient.
Description
[0001] This application is a continuation of application Ser. No.
12/119,759, filed 13 May 2008 (allowed) which is a continuation of
application Ser. No. 11/828,389, filed Jul. 26, 2007(abandoned),
which is a divisional of application Ser. No. 10/547,987, filed
Sep. 8, 2005 (U.S. Pat. No. 7,262,188), which is a 371 of
International Application No. PCT/EP2004/002554, filed Mar. 9,
2004.
BACKGROUND OF THE INVENTION
[0002] This invention relates to novel phenyl sulfone compounds
having pharmacological activity, processes for their preparation,
to compositions containing them and to their use in the treatment
of CNS and other disorders.
[0003] WO 99/37623 (SmithKline Beecham plc) and EP 930302 (F.
Hoffman La Roche) both describe a series of piperazinyl
benzenesulfone derivatives which are claimed to have affinity for
the 5-HT.sub.6 receptor. DE 4238994 (BASF) describes a series of
benzenesulfone derivatives which are claimed to be useful as
markers for fingerprinting petroleum and petroleum products.
EP602523 (Hoechst) describes a series of benzoyl guanidine
derivatives which are claimed to be useful in a variety of
cardiovascular disorders. WO 95/14004 (Pierre Fabre Medicament)
describes a series of indolyl derivatives which are claimed to have
affinity for the 5-HT.sub.1 receptor.
SUMMARY OF THE INVENTION
[0004] A structurally novel class of compounds has now been found
which also possess affinity for the 5-HT.sub.6 receptor. The
present invention therefore provides, in a first aspect, a compound
of formula (I) or a pharmaceutically acceptable salt thereof:
##STR00002##
wherein:
[0005] R.sup.1 and R.sup.2 independently represent hydrogen or
C.sub.1-6 alkyl or R.sup.1 is linked to R.sup.2 to form a group
(CH.sub.2).sub.2, (CH.sub.2).sub.3 or (CH.sub.2).sub.4;
[0006] R.sup.3 independently represents hydrogen, halogen,
C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 alkoxy, C.sub.1-6
alkylthio, C.sub.1-6 alkylsulfinyl, C.sub.1-6 alkylsulfonyl,
C.sub.1-6 alkanoyl, CN, CF.sub.3, OCH.sub.2CF.sub.3, OCF.sub.3,
hydroxyC.sub.1-6 alkyl, hydroxyC.sub.1-6 alkoxy, C.sub.1-6
alkoxycarbonyl, C.sub.1-6 alkoxyC.sub.1-6 alkoxy, nitro, amino,
C.sub.1-6 alkylamino, diC.sub.1-6 alkylamino or NR.sup.4COR.sup.5,
where R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1-6
alkyl;
[0007] m represents an integer from 1 to 5, such that wherein m is
an integer greater than 1, said R.sup.2 groups may optionally be
linked to form a group CH.sub.2, (CH.sub.2).sub.2 or
(CH.sub.2).sub.3;
[0008] n represents an integer from 1 to 4;
[0009] p represents 1 or 2;
[0010] A represents a group --Ar.sup.1 or --Ar.sup.2Ar.sup.3;
[0011] Ar.sup.1 represents unsubstituted phenyl, naphthyl
optionally substituted by 1, 2 or 3 substituents or monocyclic
heteroaryl linked to the SO.sub.2 group via a carbon atom and
optionally substituted by 1, 2 or 3 substituents;
[0012] Ar.sup.2 represents phenyl or a monocyclic heteroaryl group
linked to the SO.sub.2 group via a carbon atom, each of which may
be optionally substituted by 1, 2 or 3 substituents;
[0013] Ar.sup.3 represents a monocyclic heteroaryl group optionally
substituted by 1, 2 or 3 substituents;
[0014] substituents on Ar.sup.1, Ar.sup.2 and Ar.sup.3 are
independently selected from the group consisting of halogen,
hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C.sub.1-6
alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C.sub.1-6
alkoxy, arylC.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.1-6
alkoxyC.sub.1-6 alkyl, C.sub.3-7 cycloalkylC.sub.1-6 alkoxy,
C.sub.1-6 alkanoyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6
alkylsulfonyl, C.sub.1-6 alkylsulfinyl, C.sub.1-6 alkylsulfonyloxy,
C.sub.1-6 alkylsulfonylC.sub.1-6 alkyl, arylsulfonyl,
arylsulfonyloxy, arylsulfonylC.sub.1-6 alkyl, C.sub.1-6
alkylsulfonamido, C.sub.1-6 alkylNHCO--, C.sub.1-6
alkylCONH--C.sub.1-6 alkylsulfonamidoC.sub.1-6 alkyl, C.sub.1-6
alkylNHCOC.sub.1-6 alkyl-, C.sub.1-6 alkylCONHC.sub.1-6 alkyl-,
arylsulfonamido, arylCONH--, arylNHCO--, arylsulfonamidoC.sub.1-6
alkyl, arylCONHC.sub.1-6 alkyl, arylNHCOC.sub.1-6 alkyl, aroyl,
aroylC.sub.1-6 alkyl, arylC.sub.1-6 alkanoyl, or a group
CONR.sup.6R.sup.7 or SO.sub.2NR.sup.6R.sup.7, wherein R.sup.5 and
R.sup.7 independently represent hydrogen or C.sub.1-6 alkyl or
together may be fused to form a 5- to 7-membered aromatic or
non-aromatic heterocyclic ring optionally interrupted by an O or S
atom; or solvates thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0015] In one particular aspect of the present invention, there is
provided a compound of formula (I) as defined above wherein p
represents 1.
[0016] Specific compounds of formula (I) which may be mentioned are
those wherein A represents Ar.sup.1, Ar.sup.1 represents
unsubstituted phenyl and R.sup.3 represents halogen or
CF.sub.3.
[0017] Alkyl groups, whether alone or as part of another group, may
be straight chain or branched and the groups alkoxy and alkanoyl
shall be interpreted similarly. Alkyl moieties are more preferably
C.sub.1-4 alkyl, eg. methyl or ethyl. The term `halogen` is used
herein to describe, unless otherwise stated, a group selected from
fluorine, chlorine, bromine or iodine.
[0018] The term "aryl" includes phenyl and naphthyl.
[0019] The term "monocyclic heteroaryl" is intended to mean a 5-7
membered monocyclic aromatic ring containing 1 to 3 heteroatoms
selected from oxygen, nitrogen and sulfur. Suitable examples of
such monocyclic aromatic rings include thienyl, furyl, pyrrolyl,
triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl,
isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl,
pyridazinyl, pyrazinyl and pyridyl. Heteroaryl groups, as described
above, may be linked to the remainder of the molecule via a carbon
atom or, when present, a suitable nitrogen atom except where
otherwise indicated above.
[0020] It will be appreciated that wherein the above mentioned aryl
or heteroaryl groups have more than one substituent, said
substituents may be linked to form a ring, for example a carboxyl
and amine group may be linked to form an amide group.
[0021] Preferably R.sup.1 represents hydrogen or methyl, most
preferably hydrogen.
[0022] Preferably R.sup.2 represents hydrogen or methyl, most
preferably hydrogen.
[0023] Preferably R.sup.3 represents hydrogen or halogen, most
preferably hydrogen or a chlorine atom.
[0024] Preferably m and n both represent 1.
[0025] Preferably p represents 1.
[0026] Preferably A represents a group --Ar.sup.1.
[0027] When A represents a group --Ar.sup.1, Ar.sup.1 preferably
represents unsubstituted phenyl.
[0028] Preferred compounds according to the invention include
examples E1-E3 as shown below, or a pharmaceutically acceptable
salt thereof.
[0029] The compounds of formula (I) can form acid addition salts
thereof. It will be appreciated that for use in medicine the salts
of the compounds of formula (I) should be pharmaceutically
acceptable. Suitable pharmaceutically acceptable salts will be
apparent to those skilled in the art and include those described in
J. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts formed
with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric,
nitric or phosphoric acid; and organic acids e.g. succinic, maleic,
acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic,
methanesulfonic or naphthalenesulfonic acid. The present invention
includes within its scope all possible stoichiometric and
non-stoichiometric forms.
[0030] The compounds of formula (I) may be prepared in crystalline
or non-crystalline form, and, if crystalline, may optionally be
solvated, eg. as the hydrate. This invention includes within its
scope stoichiometric solvates (eg. hydrates) as well as compounds
containing variable amounts of solvent (eg. water).
[0031] Certain compounds of formula (I) are capable of existing in
stereoisomeric forms (e.g. diastereomers and enantiomers) and the
invention extends to each of these stereoisomeric forms and to
mixtures thereof including racemates. The different stereoisomeric
forms may be separated one from the other by the usual methods, or
any given isomer may be obtained by stereospecific or asymmetric
synthesis. The invention also extends to any tautomeric forms and
mixtures thereof.
[0032] The present invention also provides a process for the
preparation of a compound of formula (I) or a pharmaceutically
acceptable salt thereof, which process comprises:
[0033] (a) reacting a compound of formula (II)
##STR00003##
wherein R.sup.3, n and A are as defined above and L.sup.1
represents a suitable leaving group such as a halogen atom (e.g. a
chlorine, bromine or iodine atom) or a trifluoromethylsulfonyloxy
group, with a compound of formula (III)
##STR00004##
wherein R.sup.2, m and p are as defined above and R.sup.1a is as
defined for R.sup.1 or represents a suitable N-protecting group
(such as t-butyloxycarbonyl (Boc), methyl or benzyloxycarbonyl) and
thereafter as necessary removing an R.sup.1a N-protecting group;
or
[0034] (b) deprotecting a compound of formula (I) which is
protected; and optionally thereafter
[0035] (c) interconversion to other compounds of formula (I).
[0036] Process (a) typically comprises the use of a palladium,
nickel or copper catalyst, for example a mixture of a palladium
source such as Pd.sub.2(dba).sub.3 and a suitable ligand such as 2
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) or
(2-dicyclohexylphosphanylphenyl)-dimethylamine, together with a
suitable base such as sodium t-butoxide or cesium carbonate, in an
inert solvent such as 1,4-dioxane.
[0037] In process (b), examples of protecting groups and the means
for their removal can be found in T. W. Greene `Protective Groups
in Organic Synthesis` (J. Wiley and Sons, 1991). Suitable amine
protecting groups include sulfonyl (e.g. tosyl), acyl (e.g. acetyl,
2',2',2'-trichloroethoxycarbonyl, benzyloxycarbonyl or
t-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed
by hydrolysis (e.g. using an acid such as hydrochloric acid) or
reductively (e.g. hydrogenolysis of a benzyl group or reductive
removal of a 2',2',2'-trichloroethoxycarbonyl group using zinc in
acetic acid) as appropriate. Other suitable amine protecting groups
include trifluoroacetyl (--COCF.sub.3) which may be removed by base
catalysed hydrolysis or a solid phase resin bound benzyl group,
such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman
linker), which may be removed by acid catalysed hydrolysis, for
example with trifluoroacetic acid. A further amine protecting group
includes methyl which may be removed using standard methods for
N-dealkylation (e.g. 1-chloroethyl chloroformate under basic
conditions followed by treatment with methanol).
[0038] Process (c) may be performed using conventional
interconversion procedures such as epimerisation, oxidation,
reduction, alkylation, nucleophilic or electrophilic aromatic
substitution, ester hydrolysis or amide bond formation. For
example, N-dealkylation of a compound of formula (I) wherein
R.sup.1 represents an alkyl group to give a compound of formula (I)
wherein R.sup.1 represents hydrogen. It will be appreciated that
such interconversion may be interconversion of protected
derivatives of formula (I) which may subsequently be deprotected
following interconversion.
[0039] Compounds of formula (II) may be prepared by reaction of a
compound of formula (IV)
##STR00005##
wherein R.sup.3, n and L.sup.1 are as defined above and L.sup.2
represents a suitable leaving group such as a halogen atom (e.g. a
fluorine or chlorine atom), with a compound of formula A-M wherein
A is as defined above and M is a metal residue such as magnesium
halide or lithium in a suitable solvent such as
tetrahydrofuran.
[0040] Compounds of formula (III) and (IV) are either known in the
literature or can be prepared by known methods.
[0041] Pharmaceutically acceptable salts may be prepared
conventionally by reaction with the appropriate acid or acid
derivative.
[0042] Compounds of formula (I) and their pharmaceutically
acceptable salts have affinity for the 5-HT.sub.6 receptor and are
believed to be of potential use in the treatment of certain CNS
disorders such as anxiety, depression, epilepsy, obsessive
compulsive disorders, migraine, cognitive memory disorders (e.g.
Alzheimers disease, age related cognitive decline and mild
cognitive impairment), Parkinsons Disease, ADHD (Attention Deficit
Disorder/Hyperactivity Syndrome), sleep disorders (including
disturbances of Circadian rhythm), feeding disorders such as
anorexia and bulimia, panic attacks, withdrawal from drug abuse
such as cocaine, ethanol, nicotine and benzodiazepines,
schizophrenia (in particular cognitive deficits of schizophrenia),
stroke and also disorders associated with spinal trauma and/or head
injury such as hydrocephalus. Compounds of the invention are also
expected to be of use in the treatment of certain GI
(gastrointestinal) disorders such as IBS (Irritable Bowel
Syndrome). Compounds of the invention are also expected to be of
use in the treatment of obesity.
[0043] Thus the invention also provides a compound of formula (I)
or a pharmaceutically acceptable salt thereof, for use as a
therapeutic substance, in particular in the treatment or
prophylaxis of the above disorders. In particular the invention
provides for a compound of formula (I) or a pharmaceutically
acceptable salt thereof, for use in the treatment of depression,
anxiety, Alzheimers disease, age related cognitive decline, ADHD,
obesity, mild cognitive impairment, schizophrenia, cognitive
deficits in schizophrenia and stroke.
[0044] The invention further provides a method of treatment or
prophylaxis of the above disorders, in mammals including humans,
which comprises administering to the sufferer a therapeutically
effective amount of a compound of formula (I) or a pharmaceutically
acceptable salt thereof.
[0045] 5-HT.sub.6 antagonists have the potential to be capable of
increasing basal and learning-induced polysialylated neuron cell
frequency in brain regions such as the rat medial temporal lobe and
associated hippocampus, as described in WO 03/066056. Thus,
according to a further aspect of the present invention, we provide
a method of promoting neuronal growth within the central nervous
system of a mammal which comprises the step of administering a
compound of formula (I) or a pharmaceutically acceptable salt
thereof.
[0046] In another aspect, the invention provides the use of a
compound of formula (I) or a pharmaceutically acceptable salt
thereof in the manufacture of a medicament for use in the treatment
or prophylaxis of the above disorders.
[0047] In order to use the compounds of formula (I) in therapy,
they will normally be formulated into a pharmaceutical composition
in accordance with standard pharmaceutical practice. The present
invention also provides a pharmaceutical composition, which
comprises a compound of formula (I) or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable
carrier.
[0048] A pharmaceutical composition of the invention, which may be
prepared by admixture, suitably at ambient temperature and
atmospheric pressure, is usually adapted for oral, parenteral or
rectal administration and, as such, may be in the form of tablets,
capsules, oral liquid preparations, powders, granules, lozenges,
reconstitutable powders, injectable or infusable solutions or
suspensions or suppositories. Orally administrable compositions are
generally preferred.
[0049] Tablets and capsules for oral administration may be in unit
dose form, and may contain conventional excipients, such as binding
agents, fillers, tabletting lubricants, disintegrants and
acceptable wetting agents. The tablets may be coated according to
methods well known in normal pharmaceutical practice.
[0050] Oral liquid preparations may be in the form of, for example,
aqueous or oily suspension, solutions, emulsions, syrups or
elixirs, or may be in the form of a dry product for reconstitution
with water or other suitable vehicle before use. Such liquid
preparations may contain conventional additives such as suspending
agents, emulsifying agents, non-aqueous vehicles (which may include
edible oils), preservatives, and, if desired, conventional
flavourings or colourants.
[0051] For parenteral administration, fluid unit dosage forms are
prepared utilising a compound of the invention or pharmaceutically
acceptable salt thereof and a sterile vehicle. The compound,
depending on the vehicle and concentration used, can be either
suspended or dissolved in the vehicle. In preparing solutions, the
compound can be dissolved for injection and filter sterilised
before filling into a suitable vial or ampoule and sealing.
Advantageously, adjuvants such as a local anaesthetic,
preservatives and buffering agents are dissolved in the vehicle. To
enhance the stability, the composition can be frozen after filling
into the vial and the water removed under vacuum. Parenteral
suspensions are prepared in substantially the same manner, except
that the compound is suspended in the vehicle instead of being
dissolved, and sterilization cannot be accomplished by filtration.
The compound can be sterilised by exposure to ethylene oxide before
suspension in a sterile vehicle. Advantageously, a surfactant or
wetting agent is included in the composition to facilitate uniform
distribution of the compound.
[0052] The composition may contain from 0.1% to 99% by weight,
preferably from 10 to 60% by weight, of the active material,
depending on the method of administration.
[0053] The dose of the compound used in the treatment of the
aforementioned disorders will vary in the usual way with the
seriousness of the disorders, the weight of the sufferer, and other
similar factors. However, as a general guide suitable unit doses
may be 0.05 to 1000 mg, more suitably 0.05 to 200 mg, for example
20 to 40 mg; and such unit doses will preferably be administered
once a day, although administration more than once a day may be
required; and such therapy may extend for a number of weeks or
months.
[0054] All publications, including but not limited to patents and
patent applications, cited in this specification are herein
incorporated by reference as if each individual publication were
specifically and individually indicated to be incorporated by
reference herein as though fully set forth.
[0055] The following Descriptions and Examples illustrate the
preparation of compounds of the invention.
Description 1
3-Bromophenylsulfonyl fluoride (D1)
[0056] To a stirred solution of 3-bromophenylsulfonyl chloride (5
g, 0.0196 mol) in acetonitrile (20 ml) was added potassium fluoride
(2.27 g, 0.0391 mol) followed by 18-crown-6 ether (0.08 g) and the
reaction stirred at room temperature for 18 h. The reaction mixture
was then washed with water (60 ml), extracted with ethyl acetate
(3.times.80 ml) and the combined organic extracts dried
(Na.sub.2SO.sub.4). Solvents were evaporated in vacuo to give a
yellow oil (3.79 g, 81%).
[0057] .sup.1H NMR (CDCl.sub.3): .delta. 7.55 (1H, t), 7.92 (1H,
d), 7.95 (1H, d), 8.14 (1H, s).
Description 2
3-Phenylsulfonylbromobenzene (D2)
[0058] To a stirred solution of 3-bromophenylsulfonyl fluoride (D1)
(1 g, 4.18 mmol) in dry THF (20 ml) at -78.degree. C., under argon
was added phenylmagnesium bromide (1 M, 1.4 ml, 4.18 mmol)
dropwise. The reaction was left to warm to room temperature
overnight and then quenched with ammonium chloride (50 ml),
extracted with ethyl acetate (3.times.40 ml) and the combined
organic extracts dried (Na.sub.2SO.sub.4). Solvents were evaporated
in vacuo to give a colourless solid (1.09 g, 88%).
[0059] .sup.1H NMR (CDCl.sub.3): .delta. 7.40 (1H, t), 7.50-7.55
(2H, m), 7.60 (1H, d), 7.69 (1H, d), 7.86 (1H, d), 7.93 (2H, d),
8.08 (1H, s).
Description 3
1-(3-Phenylsulfonyl phenyl)-4-tert-butyloxycarbonyl piperazine
(D3)
[0060] A solution of 2 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
(BINAP) (62 mg, 0.1 mmol) and cesium carbonate (329 mg, 1.01 mmol)
in dry dioxane (2 ml) were sonicated for 45 min, under argon. To
this solution was added 3-phenylsulfonylbromobenzene (D2) (200 mg,
0.67 mmol) and 1-(tert-butyloxycarbonyl)piperazine (314 mg, 1.68
mmol) and the reaction heated at 100.degree. C. for 18 h. The
reaction mixture was evaporated in vacuo and the residue
partitioned between water (50 ml) and dichloromethane (50 ml). The
organic layer was washed with sat. sodium hydrogen carbonate (50
ml), 10% citric acid (50 ml), brine (50 ml) and then dried
(MgSO.sub.4). Solvents evaporated in vacuo and the residue purified
by column chromatography (silica gel; 0-60% ethyl acetate/petroleum
ether) to give the product as a colourless oil (192 mg, 71%)
[0061] .sup.1H NMR (CDCl.sub.3): .delta. 1.48 (9H, s), 3.15-3.20
(4H, t), 3.55-3.60 (4H, t), 7.05 (1H, m), 7.36 (2H, m), 7.45 (1H,
m), 7.50 (2H, m), 7.56 (1H, m), 7.94 (2H, d).
[0062] Mass Spectrum: C.sub.21H.sub.26N.sub.2SO.sub.4 requires 402;
found: 403 (MH.sup.+).
Description 4
4-(3-Phenylsulfonyl-2-chlorophenyl)piperazine-1-carboxylic acid
tert-butyl ester (D4A) and
4-(5-Phenylsulfonyl-2-chlorophenyl)piperazine-1-carboxylic acid
tert-butyl ester (D4B)
[0063] 1-(3-Phenylsulfonylphenyl)-4-tert-butyloxycarbonyl
piperazine (D3) (84 mg, 0.20 mmol) was dissolved in acetic acid (5
ml) and heated at 60.degree. C. Then N-chlorosuccinimide (28 mg,
0.20 mmol) was added and the stirred reaction mixture was heated at
60.degree. C. for 24 h, then cooled to ambient temperature. The
reaction mixture was diluted in dichloromethane and neutralised by
addition of an aqueous solution of NaHCO.sub.3. The organic layer
was dried with MgSO.sub.4 and evaporated in vacuo to give two main
products, which were separated by column chromatography eluting
with dichloromethane/ethyl acetate (0-30%).
[0064] Product D4A: 18 mg.
[0065] .sup.1H-NMR (CDCl.sub.3): .delta. 1.46 (9H, s), 2.92 (4H,
t), 3.53 (4H, t), 7.26 (1H, dd), 7.44 (1H, t), 7.50 (2H, tt), 7.59
(1H, tt), 7.94 (2H, dd), 8.10 (1H, dd).
[0066] Mass Spectrum: C.sub.21H.sub.25.sup.35ClN.sub.2O.sub.4S
requires 436; Found 437 (MH.sup.+).
[0067] Product D4B: 40 mg.
[0068] .sup.1H-NMR (CDCl.sub.3): .delta. 1.49 (9H, s), 3.01 (4H,
t), 3.59 (4H, t), 7.47 (1H, d), 7.49-7.54 (3H, m), 7.55 (1H, d),
7.58 (1H, tt), 7.92 (2H, m).
[0069] Mass Spectrum: C.sub.21H.sub.25.sup.35ClN.sub.2O.sub.4S
requires 436; Found 437 (MH.sup.+).
EXAMPLES
Example 1
1-(3-Phenylsulfonyl-phenyl)piperazine (E1)
[0070] A solution of
1-(3-phenylsulfonylphenyl)-4-tert-butyloxycarbonyl piperazine (D3)
(96 mg, 0.23 mmol) in 1,4-dioxane (3 ml) and 4M HCl (3 ml) was
refluxed at 60.degree. C. for 1 h. The solvents were then
evaporated in vacuo and the product dried under high vacuum to give
a yellow solid (69 mg, 96%)
[0071] .sup.1H NMR (DMSO-d.sub.6): .delta. 1.49 (9H, s), 3.21 (4H,
m), 3.44-3.47 (4H, m), 7.26 (1H, d), 7.37 (1H, d), 7.45-7.50 (2H,
m), 7.60-7.65 (2H, m), 7.65-7.70 (1H, m), 7.95-7.98 (2H, d), 9.15
(2H, br-s).
[0072] Mass Spectrum: C.sub.16H.sub.18N.sub.2SO.sub.2 requires 302;
found: 303 (MH.sup.+).
Example 2
1-(3-Phenylsulfonyl-2-chlorophenyl)piperazine (E2)
[0073] 4-(3-Phenylsulfonyl-2-chlorophenyl)piperazine-1-carboxylic
acid tert-butyl ester (D4A) was dissolved in 8 ml of 1,4-dioxane/4
M HCl 1:1. The mixture was heated at 60.degree. C. for 1 h. The
solvent was evaporated in vacuo to give the title product as a
colourless solid.
[0074] .sup.1H-NMR (CD.sub.3OD): 3.21-3.35 (8H, m), 7.53-7.69 (5H,
m), 7.90 (2H, d), 8.14 (1H, d).
[0075] Mass Spectrum: C.sub.16H.sub.17.sup.35ClN.sub.2O.sub.2S
requires 336; Found 337 (MH.sup.+).
Example 3
1-(5-Phenylsulfonyl-2-chlorophenyl)piperazine (E3)
[0076] 4-(5-Phenylsulfonyl-2-chlorophenyl)piperazine-1-carboxylic
acid tert-butyl ester (D4B) was dissolved in 8 ml of 1,4-dioxane/4
M HCl 1:1. The mixture was heated at 60.degree. C. for 1 h. The
solvent was evaporated in vacuo to give the title product as a
colourless solid.
[0077] .sup.1H-NMR (CD.sub.3OD): 3.29-3.59 (8H, m), 7.57-7.70 (6H,
m), 7.97 (2H, d).
[0078] Mass Spectrum: C.sub.16H.sub.17.sup.35ClN.sub.2O.sub.2S
requires 336; Found 337 (MH.sup.+).
[0079] Pharmacological Data
[0080] Compounds can be tested following the procedures outlined in
WO98/27081.
[0081] The compounds of Examples E1-E3 were tested and showed good
affinity for the 5-HT.sub.6 receptor, having pKi values >7.5 at
human cloned 5-HT.sub.6 receptors, in particular the compounds of
Examples E1-E2 had pKi values >8.0.
* * * * *